Samples collected from myeloma patients at first relapse registered into the Myeloma XII trial, and sent to the following central labs: 1. Central immunology laboratory, University of Birmingham - pe
The Clinical Trials dataset includes information about Clinical Trials mentioned in Springer Nature publications. See also: https://scigraph.springernature.com/explorer/datasets/data_at_a_glance/<b
Patients (N=14) with unresectable stage III/IV melanoma received escalating doses of guadecitabine 30, 45, or 60 mg/m2/day subcutaneously on days 1 to 5 every 3 weeks, and ipilimumab 3 mg/kg intraveno
